A Study to Test the Pharmacokinetics Efficacy and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures

  • STATUS
    Recruiting
  • End date
    Jan 11, 2022
  • participants needed
    42
  • sponsor
    UCB Biopharma SRL
Updated on 12 September 2021

Summary

The purpose of the study is to evaluate the pharmacokinetics (PK) of brivaracetam (BRV) in neonates who have seizures that are not adequately controlled with previous antiepileptic drug (AED) treatment, and to identify the optimal BRV dose (Exploratory Cohort) for the treatment of subjects enrolled into the Confirmatory Cohorts of this study.

Details
Condition Electroencephalographic Neonatal Seizures
Treatment Brivaracetam (BRV) iv, Brivaracetam (BRV) oral, Brivaracetam (BRV) intravenous (iv)
Clinical Study IdentifierNCT03325439
SponsorUCB Biopharma SRL
Last Modified on12 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Confirmation on video-electroencephalography (VEEG) of >= 2 minutes of cumulative electroencephalographic neonatal seizures (ENS), or >=3 identifiable ENS prior to entering the Evaluation Period, despite receiving previous antiepileptic drug treatment for the treatment of electroencephalographic seizures. The occurrence of ENS during an up to 1-hour period must be confirmed either by the local or central VEEG reader prior to drug administration. Preferably, the central VEEG reader should confirm the required ENS
Subject is male or female and must be at least 34 weeks of corrected gestational age (CGA). In addition, term neonates up to 27 days of postnatal age (PNA) and preterm neonates up to 40 weeks of CGA and 27 days of PNA can be enrolled
Subject weighs at least 2.3 kg at the time of enrollment
Subjects with or without concomitant hypothermia treatment

Exclusion Criteria

Subjects are not permitted to be enrolled in the study if any of the following
criteria are
met
Subject receiving antiepileptic drug (AED) treatment other than phenobarbital, midazolam, phenytoin, levetiracetam (60 mg/kg/day), or lidocaine for the treatment of seizures prior to or at the time of enrollment (Confirmatory Cohorts only)
Subject with seizures responding to any of the following: previous AED treatment immediately prior to BRV treatment, pyridoxine treatment, or correction of metabolic disturbances (hypoglycemia, hypomagnesemia, or hypocalcemia)
Subject requires extra corporeal membrane oxygenation
Subject has seizures related to prenatal maternal drug use or drug withdrawal
Subject has known severe disturbance of hemostasis, as assessed by the Investigator
Subject has a poor prognosis for survival, as judged by the Investigator
Subject has 2x upper limit of normal (ULN) of any of the following: aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP), with the following exception
Subject has direct (conjugated) bilirubin levels >2 mg/dL
For subjects with perinatal asphyxia, elevation of AST, ALT or ALP <5x ULN is
Subject requiring or expected to require phototherapy or exchange transfusion due to elevated bilirubin
acceptable, if initial and peak elevation of liver function tests (LFTs)
Subject with rapidly increasing bilirubin that may preclude the subject from inclusion in the study at the discretion of the Investigator
occurs within 5 days after birth, and the time course of LFT elevation is
compatible with hepatic injury due to perinatal asphyxia. The determination of
ULN will be based on the subject's gestational age (GA) and the site's normal
range values for the respective GA
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note